key: cord-1002609-ym6km57t
authors: Zhao, Lei; Zhong, Wu
title: Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
date: 2021-09-08
journal: Innovation (N Y)
DOI: 10.1016/j.xinn.2021.100165
sha: 2a83f506ad75d3387f587c8a6cf99f52db8c9539
doc_id: 1002609
cord_uid: ym6km57t

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In this study, primer extension assays were performed to investigate how FTP interfered with RNA synthesis. 3 The results showed that favipiravir acted as a purine nucleotide analog to mimic the incorporation of A and G nucleotides into nascent RNA products. However, it did not significantly inhibit RNA production, suggesting that the incorporation of favipiravir is 

Experimental treatment with Favipiravir for COVID-19: An open-label control study. Engineering (Beijing)

Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series

Structural basis of SARS-CoV-2 polymerase inhibition by favipiravir